FDA Approves New Drug for Pancreatic Cancer

0
81

The U.S. Food and Drug Administration in White Oak, Md., on June 5, 2023. Madalina Vasiliu/The Epoch Times

Federal regulators on Aug. 26 said they approved a new drug for the most common form of pancreatic cancer.

The drug, known as Rasonque and daraxonrasib, is approved to treat a cancer type responsible for about nine in 10 new pancreatic cancer cases diagnosed in the United States each year.

The approval was based in part on a phase 3 randomized, open-label clinical trial of 500 adults who had previously received treatment for the pancreatic cancer type, pancreatic adenocarcinoma.

Participants who received the drug survived for a median of 13.2 months, compared to 6.7 months in a control arm that only received chemotherapy.

Former Sen. Ben Sasse (R-Neb.), one of the trial participants, has credited the drug with helping reduce his tumor after being diagnosed with terminal pancreatic…

Read more…

LEAVE A REPLY

Please enter your comment!
Please enter your name here